L.E.K.’s Take on China Medtech: Optimistic Macro View, Short-Term Hit Hard Stephen Sunderland Read more
Related Practice MedTech Despite the COVID-19 lockdown, Stephen Sunderland foresees limited disruption 07102020100744
Article Life Sciences & Pharma Clinical Trial Design Strategies To Address Methodological Challenges in Psychedelics November 15, 2024
Executive Insights Life Sciences & Pharma Oncology BD&L: Winning in an Increasingly Competitive Environment September 12, 2024
Executive Insights Healthcare Services Navigating Asia’s Regulatory Mosaic: Achieving Excellence in Generative AI for Healthcare January 26, 2024
Executive Insights Life Sciences & Pharma Optimizing Pharmaceutical Portfolios Through M&A January 16, 2024
Video / Webinar Life Sciences & Pharma L.E.K. Look Forward - L.E.K. Talent Focused Organisational Strategy December 13, 2023
